PTSM: Pharmaceutical Technology Sourcing and Management
The company has completed a small-scale capacity expansion at its site in Charles City, IA.
On Nov. 8, 2017, Cambrex announced the completion of a small-scale capacity expansion at its Charles City, IA, site. The expansion includes the installation of two 500-gallon glass-lined reactors and a third small-scale work center.
“Small-scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” said Joe Nettleton, vice president of US operations at Cambrex, in a company press release.
This investment comes after the installation of a new pilot plant at the site in 2017 and recent announcements of expansions across other manufacturing sites, including the construction of a $24-million, 4500-ft2 highly potent active pharmaceutical ingredient manufacturing facility at the Charles City site, which is due to open in 2019.
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.